Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.045 USD | -2.34% | -7.15% | -24.64% |
09/05 | Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
06/05 | Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.64% | 206M | |
+7.25% | 113B | |
+11.00% | 106B | |
+0.87% | 22.27B | |
-12.23% | 22.22B | |
-5.71% | 19.43B | |
-37.85% | 17.87B | |
-5.97% | 17.24B | |
+7.39% | 14.29B | |
+34.90% | 12.52B |
- Stock Market
- Equities
- BLUE Stock
- News bluebird bio, Inc.
- Morgan Stanley Adjusts Price Target on Bluebird Bio to $4 From $3, Maintains Underweight Rating